Advanced Biosciences Laboratories, PATH Partner in Vaccine Production - - BioPharm International

ADVERTISEMENT

Advanced Biosciences Laboratories, PATH Partner in Vaccine Production


Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization, has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable GMP production process to produce toxicology and Phase I clinical supply at its facility located in Rockville, Maryland.

The vaccine candidate is based on IpaB/IpaD fusion protein technology developed in the laboratory of Wendy Picking, associate professor in the Department of Microbiology and Molecular Genetics at Oklahoma State University. The IpaB and IpaD proteins are highly conserved within Shigella species and, therefore, are expected to stimulate broad protective immune responses against multiple serotypes, according to ABL.

Source: ABL

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines

Click here